Their demographic and clinical data are shown inTable 1. == Table 1. prior to vaccination, serogroup-specific response rates were 76.9%, 65.5%, 51.7%, and 65% to serogroups A, C, W-135, and Y, respectively. One dose of MCV4 elicited protecting titers in the majority of patients. These data suggest that a second vaccine dose may be beneficial. == Visual Abstract == == Intro == Neisseria meningitidisremains a leading cause of bacterial meningitis among children and adults.1Current guidelines recommend that individuals at increased risk for invasive meningococcal disease (IMD) because of exposure or medical conditions receive the conjugated quadrivalent Paliperidone meningococcal vaccine (MCV4).2Risk factors for IMD include functional or anatomic asplenia, infection with human being immunodeficiency disease, antibody deficiencies, and complement deficiencies, including the use of anti-C5 therapies such as eculizumab.2,3 The immunogenicity of the MCV4 vaccine among adult hematopoietic cell transplant (HCT) recipients has not been prospectively studied. Although these individuals usually recover immunoglobulin G1 levels within a few months after transplant,4which is the predominant immunoglobulin G subclass involved in the immune response Paliperidone toN meningitidis,5these individuals remain at improved risk of illness with encapsulated organisms. Retrospective data suggest that the immune reactions to the MCV4 vaccine are poor after HCT and that a Paliperidone 2-dose regimen may be required to accomplish protecting antibody titers6; however, the immunogenicity of a solitary- Paliperidone or multiple-dose vaccine routine has not been prospectively evaluated. Given the knowledge gaps concerning the security and immunogenicity of MCV4 after HCT,7we carried out a vaccine response study among adult HCT recipients. == Methods == Individuals 18 years of age or older who underwent Rabbit Polyclonal to ZNF280C HCT at Dana-Farber Malignancy Institute and offered written educated consent to have pre- and postvaccination samples obtained were eligible. The study was authorized by the Office for Human being Research Studies at Dana-Farber Malignancy Institute. Autologous and allogeneic HCT recipients were included in this study if they received the meningococcal (organizations A, C, Y, and W-135) polysaccharide Paliperidone diphtheria-toxoid conjugate vaccine (Menactra; GlaxoSmithKline, Philadelphia, PA) after transplantation. Per institutional practice, a single dose of meningococcal vaccine is definitely given by intramuscular injection in the 1-yr HCT visit and is recorded in the individuals immunization record. To assess the immunogenicity of MCV4, pre- and postvaccination serogroup serum bactericidal antibody (SBA) titers were measured. Prevaccination titers were measured on the day of vaccination, whereas postvaccination titers were measured at their next follow-up visit 1 to 2 2 months later on. Patient serum was kept freezing at 80C until screening was performed. SBA titers were measured using serial dilutions of patient serum in the presence of human complement to determine the minimum amount antibody titer capable of killingN meningitidisin vitro. A single batch of human being complement was used for the entire study. This assay was performed in the Vaccine Evaluation Unit of Public Health England, Manchester, United Kingdom,8by staff blinded to patient characteristics. A vaccine response was defined as a fourfold increase in SBA titers between pre- and postvaccination samples as well as a postvaccination titer that would be deemed protecting (conventionally defined as SBA titers 1:8).9A seroreversion was defined as a fourfold decrease in SBA titers. The primary study end point wasN meningitidisserogroup A, C, W-135, and Y vaccine response rates after MCV4 administration. Wilcoxon signed-rank test was used to assess vaccine reactions on paired samples, and Spearmans rank correlation coefficient was used to compare vaccine reactions between serogroups. Logistic regression analysis was used to identify patient characteristics that were associated with a protecting postvaccination titer, including age, sex, type of HCT, HLA coordinating (for allogeneic HCT), ablative conditioning, day of vaccination relative to HCT, presence of graft-versus-host disease (GVHD) at time of vaccination, complete lymphocyte count, and immunosuppressant medication utilization. A multivariable model was not pursued because of the lack of statistically significant covariates on univariate analysis. Statistical analyses were carried out using JMP Pro 13.0 (SAS Institute, Gary, NC). == Results == Eighty-two HCT individuals consented to participate in the study, of which 67 underwent MCV4 vaccination between January and September 2014 and experienced combined samples available for analysis. Individuals were adopted until 1 December 2017. Their demographic and medical data are demonstrated inTable 1. == Table 1. == Baseline patient characteristics IQR, interquartile range. Additional diseases included myelofibrosis (n = 3), aplastic anemia (n = 2), and Langerhans cell histiocytosis. Systemic immunosuppression included prednisone,.